J&J's recent growth surge has come despite the LOE of Stelara. Compensating for the shortfall is Tre...
No patent protection for Stelara? No problem for J&J as Tremfya fills the void
J&J's recent growth surge has come despite the LOE of Stelara. Compensating for the shortfall is Tremfya, which topped the $2 billion mark in Q2.
Author: Fierce Pharma
Read Original Article